Profile data is unavailable for this security.
About the company
Pharma Mar SA is a Spain-based integrated biopharmaceutical company focused on oncology and committed to research and development (R&D) of antitumor drugs of marine origin. The Company, through its subsidiaries, operates three business segments: Oncology, Diagnostics and RNA interference. The Oncology segment encompasses research, develop and market anti-tumor drugs. The Diagnostics segment includes the development and marketing of diagnostic kits. The RNA interference segment consist of the development of drugs with therapeutic activity based on reducing or silencing gene expression. The Company’s product portfolio includes Yondelis and ZEPZELCA. Yondelis (trabectedin) is indicated for the treatment of advanced soft tissue sarcoma, as well as for the treatment of relapsed platinum-sensitive ovarian cancer. ZEPZELCA (lurbinectedin) is indicated for the treatment of metastatic small cell lung cancer (SCLC) with disease progression. The Company is active globally.
- Revenue in EUR (TTM)158.80m
- Net income in EUR-1.76m
- Incorporated1986
- Employees509.00
- LocationPharma Mar SAAvda. De los Reyes, 1, Pol. Ind. La MinaCOLMENAR VIEJO 28770SpainESP
- Phone+34 918466000
- Fax+34 918466001
- Websitehttps://www.pharmamar.com/es/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pliant Therapeutics Inc | 0.00 | -167.82m | 731.43m | 158.00 | -- | 2.05 | -- | -- | -3.09 | -3.09 | 0.00 | 6.50 | 0.00 | -- | -- | 0.00 | -35.03 | -33.24 | -37.15 | -35.39 | -- | -- | -- | -360.29 | -- | -- | 0.0711 | -- | -83.69 | -- | -30.83 | -- | -16.89 | -- |
| Tong Ren Tang Technologies Co Ltd | 863.91m | 75.27m | 734.50m | 4.10k | 9.76 | 0.8359 | 4.54 | 0.8502 | 0.5063 | 0.5063 | 5.81 | 5.91 | 0.5212 | 0.9835 | 5.68 | 1,814,635.00 | 7.64 | 7.68 | 12.10 | 12.32 | 42.04 | 43.50 | 14.65 | 16.11 | 2.37 | -- | 0.1443 | 39.94 | 13.04 | 6.01 | 1.25 | -2.73 | -22.26 | -0.0089 |
| Wuhan Keqian Biology Co Ltd | 126.31m | 44.38m | 737.26m | 923.00 | 16.57 | 1.48 | -- | 5.84 | 0.748 | 0.748 | 2.12 | 8.37 | 0.213 | 1.93 | 3.03 | 1,072,036.00 | 7.47 | 13.29 | 8.81 | 15.49 | 68.82 | 76.49 | 35.09 | 45.71 | 3.65 | -- | 0.0508 | 24.76 | 6.27 | 7.67 | -3.32 | 0.3556 | 27.17 | -- |
| Pharma Mar SA | 158.80m | -1.76m | 748.88m | 509.00 | -- | 3.95 | 173.03 | 4.72 | -0.10 | -0.10 | 8.98 | 10.34 | 0.47 | 0.2525 | 5.64 | 311,988.20 | -0.5212 | 18.52 | -0.701 | 25.89 | 93.42 | 93.76 | -1.11 | 28.87 | 2.01 | -- | 0.1745 | -- | -19.45 | 7.77 | -97.70 | -- | 46.37 | -- |
| Cisen Pharmaceutical Co Ltd | 571.50m | 67.45m | 754.27m | 3.40k | 11.21 | 1.00 | -- | 1.32 | 1.16 | 1.16 | 9.86 | 13.02 | 0.6082 | 2.81 | 5.65 | 1,315,959.00 | 7.21 | 6.94 | 9.02 | 8.56 | 57.33 | 56.27 | 11.85 | 10.77 | 3.12 | -- | 0.0373 | 33.42 | 9.75 | 3.22 | 48.92 | 0.697 | -15.19 | 10.72 |
| Zeria Pharmaceutical Co Ltd | 488.42m | 55.91m | 760.15m | 1.78k | 11.28 | 1.24 | 7.32 | 1.56 | 204.82 | 204.82 | 1,789.40 | 1,858.72 | 0.5418 | 1.50 | 3.71 | 44,387,400.00 | 6.20 | 3.89 | 9.82 | 6.28 | 73.22 | 71.93 | 11.44 | 7.57 | 0.8393 | -- | 0.3508 | 35.09 | 10.74 | 4.14 | 24.78 | 17.49 | 20.77 | 5.29 |
| Zhejiang Ausun Pharmaceutical Co Ltd | 107.29m | 34.92m | 765.27m | 1.17k | 21.91 | 2.58 | -- | 7.13 | 0.3295 | 0.3295 | 1.01 | 2.80 | 0.2804 | 1.09 | 3.13 | 715,880.10 | 9.13 | 9.38 | 12.03 | 12.84 | 55.25 | 53.09 | 32.55 | 27.14 | 2.16 | -- | 0.1259 | 23.53 | 6.83 | 27.35 | 7.87 | 42.07 | 24.32 | 50.48 |
| Mochida Pharmaceutical Co Ltd | 641.17m | 27.33m | 765.68m | 1.52k | 26.63 | 0.9183 | 16.98 | 1.19 | 123.93 | 123.93 | 2,908.72 | 3,593.56 | 0.6565 | 1.75 | 3.42 | 68,032,190.00 | 2.80 | 4.37 | 3.34 | 5.31 | 50.05 | 52.47 | 4.26 | 6.71 | 3.31 | -- | 0.00 | 45.16 | -0.3641 | -1.26 | -31.61 | -11.63 | 10.91 | -1.21 |
| Phibro Animal Health Corp | 921.18m | 2.19m | 769.92m | 1.94k | 352.70 | 3.31 | 22.04 | 0.8358 | 0.0595 | 0.0595 | 25.11 | 6.34 | 1.04 | 2.59 | 6.11 | 524,576.80 | 0.2473 | 3.93 | 0.3071 | 4.90 | 30.82 | 31.18 | 0.2374 | 3.77 | 1.64 | 1.76 | 0.6554 | 56.45 | 4.07 | 4.21 | -92.59 | -46.35 | 6.65 | 0.8548 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 08 Aug 2024 | 455.25k | 2.45% |
| BlackRock Fund Advisorsas of 08 Aug 2024 | 207.35k | 1.12% |
| Norges Bank Investment Managementas of 31 Dec 2023 | 201.34k | 1.09% |
| RWC Asset Management LLPas of 08 Mar 2023 | 196.41k | 1.06% |
| Dimensional Fund Advisors LPas of 08 Aug 2024 | 97.52k | 0.53% |
| BlackRock Advisors (UK) Ltd.as of 08 Aug 2024 | 63.40k | 0.34% |
| Jupiter Asset Management Ltd.as of 30 Apr 2024 | 61.13k | 0.33% |
| SSgA Funds Management, Inc.as of 08 Aug 2024 | 54.44k | 0.29% |
| DWS Investments (UK) Ltd.as of 08 Aug 2024 | 27.10k | 0.15% |
| Caixabank Asset Management SGIIC SAas of 30 Jun 2024 | 27.04k | 0.15% |
